Methylenetetrahydrofolate reductase gene polymorphism and ischemic stroke in Japanese

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 18, Issue 9, 1998, Pages 1465-1469

  Morita, Hiroyuki ^a   Kurihara, Hiroki ^a,b   Tsubaki, Shin Ichi ^c   Sugiyama, Takao ^a   Hamada, Chikuma ^b   Kurihara, Yukiko ^a   Shindo, Takayuki ^d   Oh hashi, Yoshio ^a   Kitamura, Kazuyuki ^c   Yazaki, Yoshio ^a  

^a Dept of Cardiovascular Medicine ^*  (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c Kitamura Neurosurgery Clinic   (Japan)

^d INSTITUTE FOR ADULT DISEASES   (Japan)

Author keywords

Genetics; Homocysteine; Methylenetetrahydrofolate reductase; Risk factors; Stroke

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2);

ADULT; AGED; ARTICLE; BRAIN INFARCTION; CORONARY ARTERY DISEASE; CORONARY RISK; DNA POLYMORPHISM; ENZYME ACTIVITY; FEMALE; GENE MUTATION; GENETICS; HUMAN; ISCHEMIC HEART DISEASE; JAPAN; MAJOR CLINICAL STUDY; MALE; METHYLATION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STROKE;

EID: 17344372005     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.18.9.1465     Document Type: Article

References (20)

1. Kodama K. Stroke trends in Japan. Ann Epidemiol. 1993;3:524-528.
2. Hirano T, Oita J, Yamaguchi T. Classification of ischemic stroke and frequency distribution. Jpn J Clin Med. 1993;51(suppl):337-342 (in Japanese).
3. Fujishima M. Cerebrovascular disorders among Japanese. J Jpn Soc Intern Med. 1996;85:1407-1418 (in Japanese).
4. Welin L, Svardsudd K, Wilhelmsen L, Larsson B, Tibblin G. Analysis of risk factors for stroke in a cohort of men born in 1913. N Engl J Med. 1987;317:521-526.
5. Fujishima M, Kiyohara Y, Kato I, Ohmura T, Iwamoto H, Nakayama K, Ohmori S, Yoshitake T. Diabetes and cardiovascular disease in a prospective population survey in Japan: the Hisayama Study. Diabetes. 1996;45(suppl 3):S14-S16.
6. Robbins AS, Manson JE, Lee IM, Satterfield S, Hennekens CH. Cigarette smoking and stroke in a cohort of US male physicians. Ann Intern Med. 1994;120:458-462.
7. McCully KS. Homocysteine and vascular disease. Nat Med. 1996;2:386-389.
8. Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol. 1996;27:517-527.
9. Boers GH, Smals AG, Trijbels FJ, Fowler B, Bakkeren JA, Schoonderwaldt HC, Kleijer WJ, Kloppenborg PW. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med. 1985;313:709-715.
10. Malinow MR, Kang SS, Taylor LM, Wong PWK, Coull B, Inahara T, Mukerjee D, Sexton G, Upson B. Prevalence of hyperhomocyst(e)inemia in patients with peripheral arterial occlusive disease. Circulation. 1989;79:1180-1188.
11. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991;324:1149-1155.
12. Selhub J, Jacques PF, Bostom AG, D'Agostino RB, Wilson PW, Belanger AJ, O'Leary DH, Wolf PA, Schaefer EJ, Rosenberg IH. Association between plasma homocysteine concentrations and extracranial carotidartery stenosis. N Engl J Med. 1995;332:286-291.
13. den Heijer M, Koster T, Blom HJ, Bos GMJ, Briet E, Reitsma PH, Vandenbroucke JP, Rosendaal FR. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med. 1996;334:759-762.
14. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D, Tishler PV, Hennekens CH. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA. 1992;268:877-881.
15. Mudd SH, Skovby F, Levy HL, Pettigrew KD, Wilcken B, Pyeritz RE, Andria G, Boers GH, Bromberg IL, Cerone R, Fowler B, Grobe H, Schmidt H, Schweitzer L. The natural history of homocystinuria due to cystathionine β-synthase deficiency. Am J Hum Genet. 1985;37:1-31.
16. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet. 1995;346:1395-1398.
17. Brattstrom L, Lindgren A, Israelsson B, Malinow MR, Norrving B, Upson B, Hamfelt A. Hyperhomocysteinaemia in stroke: prevalence, cause, and relationships to type of stroke and stroke risk factors. Eur J Clin Invest. 1992;22:214-221.
18. Coull BM, Malinow MR, Beamer N, Sexton G, Nordt F, de Garmo P. Elevated plasma homocyst(e)ine concentration as a possible independent risk factor for stroke. Stroke. 1990;21:572-576.
19. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluijtmans LA, van den Heuvel LP, Rozen R. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10:111-113.
20. Wilcken DEL, Wang XL, Sim AS, McCredie RM. Distribution in healthy and coronary populations of the methylenetetrahydrofolate reductase (MTHFR) C677T mutation. Arterioscler Thromb Vasc Biol. 1996;16:878-882.